|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FAM64A |
Gene summary for FAM64A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FAM64A | Gene ID | 54478 |
| Gene name | PICALM interacting mitotic regulator | |
| Gene Alias | CATS | |
| Cytomap | 17p13.2 | |
| Gene Type | protein-coding | GO ID | GO:0007049 | UniProtAcc | A0A0S2Z5F0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54478 | FAM64A | P2T-E | Human | Esophagus | ESCC | 3.97e-04 | 1.56e-01 | 0.1177 |
| 54478 | FAM64A | P4T-E | Human | Esophagus | ESCC | 8.33e-13 | 5.16e-01 | 0.1323 |
| 54478 | FAM64A | P9T-E | Human | Esophagus | ESCC | 1.88e-05 | 1.80e-01 | 0.1131 |
| 54478 | FAM64A | P10T-E | Human | Esophagus | ESCC | 1.97e-10 | 2.62e-01 | 0.116 |
| 54478 | FAM64A | P16T-E | Human | Esophagus | ESCC | 7.90e-03 | 1.44e-01 | 0.1153 |
| 54478 | FAM64A | P21T-E | Human | Esophagus | ESCC | 1.47e-14 | 5.39e-01 | 0.1617 |
| 54478 | FAM64A | P22T-E | Human | Esophagus | ESCC | 1.66e-02 | 1.26e-01 | 0.1236 |
| 54478 | FAM64A | P24T-E | Human | Esophagus | ESCC | 4.44e-08 | 2.71e-01 | 0.1287 |
| 54478 | FAM64A | P28T-E | Human | Esophagus | ESCC | 4.17e-05 | 1.26e-01 | 0.1149 |
| 54478 | FAM64A | P30T-E | Human | Esophagus | ESCC | 2.13e-03 | 3.41e-01 | 0.137 |
| 54478 | FAM64A | P31T-E | Human | Esophagus | ESCC | 2.06e-08 | 3.32e-01 | 0.1251 |
| 54478 | FAM64A | P32T-E | Human | Esophagus | ESCC | 9.67e-18 | 5.76e-01 | 0.1666 |
| 54478 | FAM64A | P37T-E | Human | Esophagus | ESCC | 1.42e-10 | 3.14e-01 | 0.1371 |
| 54478 | FAM64A | P52T-E | Human | Esophagus | ESCC | 1.88e-04 | 1.78e-01 | 0.1555 |
| 54478 | FAM64A | P54T-E | Human | Esophagus | ESCC | 2.11e-02 | 1.07e-01 | 0.0975 |
| 54478 | FAM64A | P61T-E | Human | Esophagus | ESCC | 2.42e-03 | 1.36e-01 | 0.099 |
| 54478 | FAM64A | P62T-E | Human | Esophagus | ESCC | 2.57e-02 | 1.58e-01 | 0.1302 |
| 54478 | FAM64A | P74T-E | Human | Esophagus | ESCC | 3.33e-12 | 8.86e-01 | 0.1479 |
| 54478 | FAM64A | P76T-E | Human | Esophagus | ESCC | 9.20e-06 | 3.77e-01 | 0.1207 |
| 54478 | FAM64A | P79T-E | Human | Esophagus | ESCC | 9.53e-09 | 2.84e-01 | 0.1154 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FAM64A | deletion | Frame_Shift_Del | novel | c.618delN | p.Ala208ArgfsTer13 | p.A208Rfs*13 | Q9BSJ6 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| FAM64A | SNV | Missense_Mutation | novel | c.581G>T | p.Cys194Phe | p.C194F | Q9BSJ6 | protein_coding | deleterious(0.01) | probably_damaging(0.967) | TCGA-C5-A8ZZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unspecific | Cisplatin | SD |
| FAM64A | SNV | Missense_Mutation | c.41G>A | p.Arg14Gln | p.R14Q | Q9BSJ6 | protein_coding | tolerated(0.38) | probably_damaging(0.992) | TCGA-DG-A2KM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| FAM64A | SNV | Missense_Mutation | rs779599791 | c.34G>A | p.Val12Met | p.V12M | Q9BSJ6 | protein_coding | tolerated(0.97) | benign(0.024) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| FAM64A | SNV | Missense_Mutation | novel | c.589N>G | p.Ser197Gly | p.S197G | Q9BSJ6 | protein_coding | tolerated(0.25) | possibly_damaging(0.527) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| FAM64A | SNV | Missense_Mutation | rs143072744 | c.191N>A | p.Arg64His | p.R64H | Q9BSJ6 | protein_coding | tolerated(0.45) | benign(0.367) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FAM64A | deletion | Frame_Shift_Del | c.601_602delAG | p.Ser201Ter | p.S201* | Q9BSJ6 | protein_coding | TCGA-AA-3986-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |||
| FAM64A | deletion | In_Frame_Del | c.377_379delNNN | p.Lys127del | p.K127del | Q9BSJ6 | protein_coding | TCGA-D5-6530-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |||
| FAM64A | SNV | Missense_Mutation | rs11538170 | c.211N>T | p.Arg71Cys | p.R71C | Q9BSJ6 | protein_coding | deleterious(0.02) | probably_damaging(0.91) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| FAM64A | SNV | Missense_Mutation | novel | c.116N>A | p.Ser39Tyr | p.S39Y | Q9BSJ6 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |